- Conditions
- Infections, Bacterial
- Interventions
- AVA, Raxibacumab, Diphenhydramine
- Biological · Drug
- Lead sponsor
- Emergent BioSolutions
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 573 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 3
- States / cities
- Edgewater, Florida • Overland Park, Kansas • Knoxville, Tennessee
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 29
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Plasma Cell Leukemia, Myelodysplastic Syndromes, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, B-Cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia, Lymphoblastic Lymphoma, Burkitt's Lymphoma, Non-Hodgkin's Lymphoma, Multiple Myeloma, Myeloproliferative Syndromes, Hematological Diseases
- Interventions
- Allopurinol, Fludarabine, Cyclophosphamide, ATG, TBI, Tacrolimus, MMF, Peripheral Blood Stem Cells, Related or Unrelated Bone Marrow Cells
- Drug · Radiation · Biological
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 75 Years
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Multiple Myeloma
- Interventions
- Elotuzumab, Lenalidomide, autologous PBMC reconstitution, ASCT
- Drug · Other
- Lead sponsor
- Hearn Jay Cho
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Prostate Cancer
- Interventions
- huJ591
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Non-small Cell Lung Cancer With STK11/LKB1 Mutation
- Interventions
- Daratumumab and Hyaluronidase-fihj, Pre-Intervention Medication, Post-Intervention Medication
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Interventions
- anti-thymocyte globulin, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic HSCT
- Biological · Drug · Procedure
- Lead sponsor
- Northside Hospital, Inc.
- Other
- Eligibility
- Up to 75 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Acute Urticaria
- Interventions
- JDP-205 Injection, Diphenhydramine
- Drug
- Lead sponsor
- JDP Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 2
- States / cities
- Cincinnati, Ohio • Columbus, Ohio
- Conditions
- Anemia, Sickle Cell
- Interventions
- Siplizumab, Exchange Transfusion, Total Body Irradiation, Stem Cell Infusion, Cyclophosphamide 50mg, Mesna, Sirolimus Oral Tablet, Rituximab or Biosimilar
- Drug · Procedure
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- HPV-Related Squamous Cell Carcinoma, HNSCC
- Interventions
- nab-paclitaxel, Carboplatin, Nivolumab, Cisplatin, Hydroxyurea, 5-FU, Dexamethasone, Famotidine, Diphenhydramine, Paclitaxel, Transoral robotic surgery (TORS), Adjuvant RT, Chemoradiotherapy
- Drug · Procedure · Radiation
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Systemic Lupus Erythematosus, Systemic Sclerosis
- Interventions
- Nonmyeloablative allogeneic stem cell transplant
- Procedure
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2015
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Colonoscopy, Adjunct Anesthesia Medication
- Interventions
- Diphenhydramine, Placebo
- Drug
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Rheumatoid Arthritis
- Interventions
- rituximab, methotrexate, methylprednisolone, acetaminophen, antihistamine
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 351 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 86
- States / cities
- Birmingham, Alabama • Tuscaloosa, Alabama • Gilbert, Arizona + 77 more
- Conditions
- Primary Membranous Nephropathy
- Interventions
- Obinutuzumab, Tacrolimus, Methylprednisolone, Acetaminophen, Diphenhydramine
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 8
- States / cities
- San Francisco, California • Aurora, Colorado • Altamonte Springs, Florida + 5 more
- Conditions
- Headache
- Interventions
- Normal Saline 5mL, Normal Saline 20mL/kg, Prochlorperazine 0.15 mg/kg up to 10 mg IV, Diphenhydramine 1 mg/kg up to 50 mg IV
- Drug
- Lead sponsor
- University Medical Center of Southern Nevada
- Other
- Eligibility
- 10 Years to 65 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada
- Conditions
- Lung Cancer
- Interventions
- cetuximab
- Biological
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 157
- States / cities
- Aurora, Colorado • Colorado Springs, Colorado • Denver, Colorado + 107 more
- Conditions
- Acute Urticaria
- Interventions
- Test Drug (JDP-205), Active Control (Diphenhydramine)
- Drug
- Lead sponsor
- JDP Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 262 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 3
- States / cities
- Cincinnati, Ohio • Philadelphia, Pennsylvania • Dallas, Texas
- Conditions
- Oncology Patients Receiving Chemotherapy
- Interventions
- Cetirizine HCl 10 mg/mL, Diphenhydramine 50 mg/mL, anti-CD20 such as Rituximab or Paclitaxel
- Drug
- Lead sponsor
- TerSera Therapeutics LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 7
- States / cities
- Napa, California • Rancho Mirage, California • Santa Rosa, California + 4 more
- Conditions
- Recurrent Medulloblastoma, Recurrent Ependymoma
- Interventions
- Irinotecan, Temozolomide, Bevacizumab, Omburtamab I-131, Liothyronine, SSKI, Dexamethasone, Antipyretic, Antihistamine, anti-emetics
- Drug
- Lead sponsor
- Pediatric Brain Tumor Consortium
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 3
- States / cities
- Los Angeles, California • New York, New York • Cincinnati, Ohio
- Conditions
- Kidney Transplant
- Interventions
- Infliximab, Methylprednisolone, Mycophenolate Mofetil, Tacrolimus, Thymoglobulin®, Acetaminophen, Loratadine, Placebo for Infliximab, Prednisone, Diphenhydramine
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 290 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 8 more
- Conditions
- Lung Cancer, Lung Nodule, Non Small Cell Lung Cancer
- Interventions
- SGM-101, Near infrared camera imaging system
- Drug · Device
- Lead sponsor
- Sunil Singhal
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Sickle Cell Disease, Graft Versus Host Disease
- Interventions
- Diphenhydramine, Acetaminophen, Methylprednisolone, Meperidine, Alemtuzumab, Thymoglobulin, Fludarabine, Melphalan, Thiotepa, Cyclosporine, Tacrolimus, Methotrexate, Abatacept, Marrow infusion, Sirolimus, Mycophenolate Mofetil
- Drug · Procedure
- Lead sponsor
- Monica Bhatia
- Other
- Eligibility
- 3 Years to 20 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 7
- States / cities
- Washington D.C., District of Columbia • Atlanta, Georgia • Chicago, Illinois + 4 more
- Conditions
- Urinary Bladder Neoplasms
- Interventions
- Durvalumab, Vicineum, Acetaminophen, Antihistamine, Bladder Biopsy, TURBT, Cystoscopy, Urine cytology, Electrocardiogram, CT, MRI
- Drug · Procedure · Diagnostic Test
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Renal Transplant
- Interventions
- Belatacept, Sirolimus, Anti-thymocyte globulin, methylprednisolone
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 2
- States / cities
- San Francisco, California • Atlanta, Georgia
- Conditions
- Hematologic Malignancies
- Interventions
- CliniMACS® CD34 Reagent System, Fludarabine, Melphalan, anti-thymocyte globulin (rabbit), Rituximab, Total Body Irradiation, Mycophenolate Mofetil, Tacrolimus
- Device · Drug · Radiation
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2026
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • New York, New York